Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
30 participants
INTERVENTIONAL
2009-02-28
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics and Safety Study of Probucol by Multiple Administration in Healthy Male Subjects
NCT01590901
Safety and Pharmacokinetics of Probucol and Cilostazol
NCT00549978
[14C] Icosabutate -A Phase I Absorption, Metabolism and Excretion Study
NCT02373176
Safety, Pharmacokinetic Study of PRIC in Healthy Adult Subjects
NCT03826485
Phase I/II Clinical Trial of NPF-08 in Healthy Volunteers
NCT03423771
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
Group 2(probucol 500mg BID)
probucol
group 2: 250 mg 2 tablets at once in the morning
1
Group 1(Probucol 250mg)
probucol
group 1: 250 mg
3
Group 3(Probucol 500mg once daily)
probucol
group 3: 250 mg 1 tablet in the morning and evening
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
probucol
group 3: 250 mg 1 tablet in the morning and evening
probucol
group 1: 250 mg
probucol
group 2: 250 mg 2 tablets at once in the morning
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male
* Age from 20 to 40 years at time of informed consent
* BMI more than 19.0 and less than 25.0
* Subjects who meet the following criteria at the time of the screening
* Subjects with ECG results without AV block and with both of qTc and QRS width within the standard values
Exclusion Criteria
* Present or previous significant drug allergy to any prescription or OTC medication
20 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea Otsuka Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyung-Sang Yoo, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Clinical Trial Center, Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul national univeristy
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
009-KOB-0801i
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.